C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 114 filers reported holding C4 THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $598,193 | -19.4% | 321,609 | +19.2% | 0.00% | – |
| Q2 2023 | $741,956 | +45.3% | 269,802 | +65.9% | 0.00% | – |
| Q1 2023 | $510,721 | -68.0% | 162,650 | -39.8% | 0.00% | -100.0% |
| Q4 2022 | $1,594,298 | -42.7% | 270,220 | -14.8% | 0.00% | 0.0% |
| Q3 2022 | $2,780,000 | -2.3% | 317,045 | -15.9% | 0.00% | 0.0% |
| Q2 2022 | $2,844,000 | -64.4% | 377,186 | +14.4% | 0.00% | -66.7% |
| Q1 2022 | $7,995,000 | -27.6% | 329,578 | -3.9% | 0.00% | 0.0% |
| Q4 2021 | $11,038,000 | -40.8% | 342,798 | -17.9% | 0.00% | -50.0% |
| Q3 2021 | $18,647,000 | +22.8% | 417,353 | +4.0% | 0.01% | +20.0% |
| Q2 2021 | $15,188,000 | +56.4% | 401,373 | +52.9% | 0.01% | +66.7% |
| Q1 2021 | $9,708,000 | +191.0% | 262,438 | +160.6% | 0.00% | +200.0% |
| Q4 2020 | $3,336,000 | – | 100,716 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |